Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: We wish to provide the following
factual corrections in response to the article by Dr Inglesby and colleagues1 about anthrax as a biological weapon.
First, Inglesby et al state that there are no US Food and Drug Administration
(FDA)–approved postexposure antibiotic regimens following exposure to
a Bacillus anthracis aerosol. In fact, on August
30, 2000, the FDA approved ciprofloxacin for use in inhalational anthrax (postexposure)
for both adults and children. (Inhalational anthrax postexposure is also referred
to as anthrax postexposure prophylaxis [PEP].)
Meyerhoff A, Murphy D. Guidelines for Treatment of Anthrax. JAMA. 2002;288(15):1848-1849. doi:10.1001/jama.288.15.1845